glp-1 face How to Treat After Weight Loss: Filler & Sculptra Aesthetic restoration following GLP-1 agonist–induced
Description
Novo Nordisk, EVOKE and EVOKE+ phase 3 trial topline results, Alzheimers Association statement, 2025
After their success in the obesity field, GLP-1 agonists are gaining interest in addiction treatment
Several multi-targeting agonists at GIPR, GLP-1R or GCGR, developed to maximize metabolic benefits with reduced side-effects, are in clinical trials to treat type 2 diabetes and obesity
Survodutide also reduced waist circumference, an indicator of metabolic health.
To get the most out of GLP-1 medications, its important to follow a diet that complements their effects while supporting your overall health
